Neurohormonal inhibition in heart failure: insights from recent clinical trials

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure (HF) involves persistent neuroendocrine system activation, linked to disease progression.
• Adrenergic modulators (ACE inhibitors, ARBs, beta-blockers) improve HF outcomes.
• This led to the hypothesis that inhibiting single neurohormonal pathways offers incremental benefits.

Purpose of the Study:

• To evaluate the efficacy and safety of selective neurohormonal inhibition in heart failure.
• To explore the reasons behind the limited benefits of certain neurohormonal antagonists.

Main Methods:

• Review of clinical trials involving adrenergic modulators and centrally acting agents.
• Analysis of outcomes associated with endopeptidase inhibitors, endothelin antagonists, and cytokine antagonists.

Main Results:

• Established HF therapies targeting neurohormonal systems provide long-term benefits.
• Recent trials with selective neurohormonal inhibitors (e.g., endothelin antagonists) suggest potential adverse effects and limited advantages.
• Selective inhibition may not be beneficial and could be detrimental.

Conclusions:

• The long-term mortality benefits in chronic heart failure are primarily achieved by treating the underlying causes of HF.
• Selective inhibition of neurohormonal systems may not be as effective as initially hypothesized and carries risks.
• Future research should focus on comprehensive management of HF etiology rather than solely targeting individual neurohormonal pathways.